ReviewDigital health
Digital health and metaverse for Alzheimer's disease and related dementia: A scoping review.
Review in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The metaverse, an emerging digital ecosystem that integrates virtual reality (VR) and augmented reality (AR), is gaining increasing attention in the healthcare industry. In Alzheimer's disease and related dementias (AD/ADRD) care, the metaverse offers transformative solutions for cognitive assessment, remote monitoring, caregiver education, and patient engagement. Objective: A comprehensive scoping review was conducted following the PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines to systematically identify, select, and synthesize relevant literature exploring how emerging digital solutions, including digital health and metaverse applications, are addressing clinical challenges associated with AD/ADRD. Methods: Searches were conducted across online databases including PubMed, IEEE Xplore, ACM Digital Library, and Google Scholar (with a restricted search strategy due to the high volume of available literature), yielding a total of 160 hit results. Of these, 18 relevant articles were selected for in-depth analysis. Results: Findings highlight that immersive virtual environments enable individuals with AD/ADRD to engage in cognitive training programs and simulations, aiding memory and cognitive function. Additionally, VR-based telemedicine enables patients to consult with healthcare professionals from the comfort of their homes, reducing travel burdens and ensuring continued medical care despite geographical constraints. Beyond direct patient benefits, the metaverse supports caregivers through virtual training, educational resources, and peer networks that help them navigate the complexities of dementia care. Virtual spaces promote social interaction, reducing isolation and enhancing well-being. However, adoption barriers include technological unfamiliarity, cognitive and physical limitations, caregiver concerns, privacy and cost-related challenges. Conclusion: Personalized technology design, structured learning environments, and caregiver training can enhance adoption and effectiveness. To maximize impact, addressing barriers through education, improved accessibility, and tailored interventions is essential. Future research should explore scalable implementation strategies, assess long-term patient outcomes, and evaluate cost-effectiveness to support widespread adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.